Hedge Fund - Deerfield Management

The U.S equities markets have seriously pulled back lately, so hedge funds and other investors are stumbling upon a greater number of quality investing opportunities.

In a recent filing with the Securities and Exchange Commission (SEC), James E.

James E. Flynn’s Deerfield Management has filed a Schedule 13G disclosing a 3.66% ownership stake in the newly public company Global Blood Therapeutics Inc.

James E. Flynn’s Deerfield Management has filed a 13G with the U.S. Securities and Exchange Commission regarding its ownership of shares of Imprivata Inc. (NYSE:IMPR).

James E. Flynn’s Deerfield Management disclosed that it has upped its position in Neos Therapeutics Inc.

Constantly on the hunt for biotechnology stocks, James E. Flynn has identified another potential winner.

Deerfield Management, led by James E. Flynn, has increased its stake in Streamline Health Solutions Inc. (NASDAQ:STRM). In a newly-amended 13G filing with the U.S.

According to a recent filing with the Securities and Exchange Commission, James E. Flynn's Deerfield Management has acquired about 2.47 million shares of Healthways, Inc.

Ken Griffin's (pictured) Citadel Investment Group has acquired about 1.09 million shares of 8Point3 Energy Partners LP (NASDAQ:CAFD).